Compare Sterling Biotech with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs LUPIN - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH LUPIN STERLING BIOTECH/
LUPIN
 
P/E (TTM) x -0.4 108.2 - View Chart
P/BV x 0.0 2.5 0.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 STERLING BIOTECH   LUPIN
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
LUPIN
Mar-19
STERLING BIOTECH/
LUPIN
5-Yr Chart
Click to enlarge
High Rs11986 1.1%   
Low Rs3720 0.5%   
Sales per share (Unadj.) Rs26.8369.5 7.3%  
Earnings per share (Unadj.) Rs-15.013.4 -111.6%  
Cash flow per share (Unadj.) Rs-5.537.4 -14.6%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs54.9303.7 18.1%  
Shares outstanding (eoy) m267.87452.49 59.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.32.3 11.2%   
Avg P/E ratio x-0.563.6 -0.7%  
P/CF ratio (eoy) x-1.322.8 -5.6%  
Price / Book Value ratio x0.12.8 4.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,862386,064 0.5%   
No. of employees `0001.417.7 7.7%   
Total wages/salary Rs m54731,513 1.7%   
Avg. sales/employee Rs Th5,303.39,453.8 56.1%   
Avg. wages/employee Rs Th403.81,782.0 22.7%   
Avg. net profit/employee Rs Th-2,959.0343.0 -862.7%   
INCOME DATA
Net Sales Rs m7,181167,182 4.3%  
Other income Rs m433,640 1.2%   
Total revenues Rs m7,223170,822 4.2%   
Gross profit Rs m94728,822 3.3%  
Depreciation Rs m2,54310,850 23.4%   
Interest Rs m4,3773,078 142.2%   
Profit before tax Rs m-5,93118,534 -32.0%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m-1,9249,017 -21.3%   
Profit after tax Rs m-4,0076,066 -66.1%  
Gross profit margin %13.217.2 76.5%  
Effective tax rate %32.448.7 66.7%   
Net profit margin %-55.83.6 -1,537.9%  
BALANCE SHEET DATA
Current assets Rs m14,335138,536 10.3%   
Current liabilities Rs m49,80961,299 81.3%   
Net working cap to sales %-494.046.2 -1,069.3%  
Current ratio x0.32.3 12.7%  
Inventory Days Days40384 481.5%  
Debtors Days Days171112 151.8%  
Net fixed assets Rs m55,432127,516 43.5%   
Share capital Rs m268905 29.6%   
"Free" reserves Rs m13,935136,517 10.2%   
Net worth Rs m14,701137,422 10.7%   
Long term debt Rs m9,47866,417 14.3%   
Total assets Rs m73,988279,494 26.5%  
Interest coverage x-0.47.0 -5.1%   
Debt to equity ratio x0.60.5 133.4%  
Sales to assets ratio x0.10.6 16.2%   
Return on assets %0.53.3 15.3%  
Return on equity %-27.34.4 -617.4%  
Return on capital %-6.48.9 -72.1%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86059,414 3.1%   
Fx outflow Rs m2522,282 0.1%   
Net fx Rs m1,83537,132 4.9%   
CASH FLOW
From Operations Rs m1,71916,660 10.3%  
From Investments Rs m-3,148-32,825 9.6%  
From Financial Activity Rs m1,4267,441 19.2%  
Net Cashflow Rs m-3-8,724 0.0%  

Share Holding

Indian Promoters % 33.9 46.6 72.7%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 0.0 11.3 -  
FIIs % 9.9 31.9 31.0%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 10.1 389.1%  
Shareholders   21,482 98,259 21.9%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  GLENMARK PHARMA  ABBOTT INDIA  STRIDES PHARMA SCIENCE  

Compare STERLING BIOTECH With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 72 Points Lower; Capital Goods and Auto Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day marginally lower.

Related Views on News

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH - WYETH LTD COMPARISON

COMPARE STERLING BIOTECH WITH

MARKET STATS